Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Neoplasms by Site 3Colorectal Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Non-Small-Cell Lung 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Pancreatic Neoplasms 1Pancreatic Diseases 1Mesothelioma, Malignant 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Colonic Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Hepatocellular 1Bronchial Neoplasms 1Advanced Gastrointestinal Cancer 1

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Gastrointestinal Cancer × napabucasin × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡